CTLA4 and neoplasm: In this study, we report two findings: i) systemic delivery of anti-CTLA4 antibodies or intratumoral expression has different effects in non-tolerized and tolerized mouse tumor models and ii) HSC-mediated anti-CTLA4 expression triggers immunosuppressive mechanisms, which facilitate tumor progression.